| scholarly article | Q13442814 |
| P50 | author | Robert D. Gibbons | Q46996511 |
| P2093 | author name string | J John Mann | |
| P2860 | cites work | Suicidal behavior and depression in smoking cessation treatments | Q21089921 |
| Nicotine receptor partial agonists for smoking cessation | Q24200322 | ||
| Longitudinal data analysis for discrete and continuous outcomes | Q29547235 | ||
| Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal | Q30433175 | ||
| Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. | Q33508060 | ||
| Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study | Q34608030 | ||
| Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis | Q34617901 | ||
| A preliminary benefit-risk assessment of varenicline in smoking cessation | Q37399078 | ||
| Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned? | Q37868003 | ||
| A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo | Q48917835 | ||
| Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System | Q50748859 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | varenicline | Q411330 |
| P304 | page(s) | 1460-1467 | |
| P577 | publication date | 2013-12-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Varenicline, smoking cessation, and neuropsychiatric adverse events | |
| P478 | volume | 170 |
| Q39333786 | Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations |
| Q26747804 | Are Smoking Cessation Treatments Associated with Suicidality Risk? An Overview |
| Q36665194 | Cancer screening, prevention, and treatment in people with mental illness |
| Q36486726 | Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation |
| Q48518738 | Differential effects of α4β2 nicotinic receptor antagonists and partial-agonists on contextual fear extinction in male C57BL/6 mice |
| Q40523144 | Effects of Televised Direct-to-Consumer Advertising for Varenicline on Prescription Dispensing in the United States, 2006-2009. |
| Q47554209 | Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial |
| Q36711713 | Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis |
| Q46301289 | Evaluation of Prolonged Exposure to Varenicline in Adult Rats: Hematological, Biochemical and Anatomopathological Studies |
| Q24658591 | Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial |
| Q51039528 | Funding a smoking cessation program for Crohn's disease: an economic evaluation. |
| Q38720906 | How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis |
| Q49897203 | Improvement of Smoking Abstinence Rates With Increased Varenicline Dosage: A Propensity Score-Matched Analysis. |
| Q36377890 | Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review |
| Q34014716 | Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. |
| Q88474223 | Managing smoking cessation |
| Q34523702 | Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial |
| Q88960570 | New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice |
| Q24185773 | Nicotine receptor partial agonists for smoking cessation |
| Q28078315 | Non-psychotropic medication and risk of suicide or attempted suicide: a systematic review |
| Q89500595 | Pharmacotherapy for smoking cessation in schizophrenia: a systematic review |
| Q36590602 | Quitting smoking before and after varenicline: a population study based on two representative samples of US smokers |
| Q33854297 | Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics |
| Q50559251 | Reframing the varenicline question: have anecdotes and emotional filters clouded our decision making? |
| Q28083649 | Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis |
| Q37589870 | Role of nicotine receptor partial agonists in tobacco cessation. |
| Q48035710 | Safety of smoking cessation drugs for mentally ill patients |
| Q40587312 | Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis |
| Q26785461 | Smoking Use and Cessation Among People with Serious Mental Illness |
| Q38290164 | Smoking and mental illness. An update for psychiatrists |
| Q53825728 | The effectiveness and safety of combining varenicline with nicotine e-cigarettes for smoking cessation in people with mental illnesses and addictions: study protocol for a randomised-controlled trial. |
| Q93106439 | The risk of varenicline-induced seizure among those who have attempted to quit smoking using pharmacotherapy |
| Q38682466 | The safety of treatments for tobacco use disorder |
| Q35226577 | Tobacco use and cessation for cancer survivors: an overview for clinicians |
| Q34725293 | Tobacco use treatment in primary care patients with psychiatric illness |
| Q35701489 | Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices |
| Q38736026 | Treatment with bupropion and varenicline for smoking cessation and the risk of acute cardiovascular events and injuries: a Swedish case-crossover study |
| Q35977030 | Trends in Use of Medications for Smoking Cessation in Medicare, 2007-2012 |
| Q38729731 | Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States |
| Q26773281 | Update on medicines for smoking cessation |
| Q38342207 | Use of Varenicline in Smokeless Tobacco Cessation: A Systematic Review and Meta-Analysis. |
| Q35516430 | Use of pharmacotherapies for smoking cessation: analysis of pregnant and postpartum Medicaid enrollees |
| Q35747407 | Use of stop-smoking medications in the United States before and after the introduction of varenicline |
| Q28552053 | Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial |
| Q28646213 | Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study |
| Q28255130 | Varenicline as a Cause of Suicidal Outcomes |
| Q38797685 | Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis |
| Q26751374 | Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence |
| Q35219810 | Varenicline in the treatment of alcohol use disorders |
| Q35791022 | Why Don't Smokers Want Help to Quit? A Qualitative Study of Smokers' Attitudes towards Assisted vs. Unassisted Quitting |
Search more.